At the same time, the use of PARP inhibitors (PARPi) in patients with germline BRCA1/2 mutation (gBRCAm) is the standard of care in the metastatic and adjuvant settings of high-risk patients with HER2-negative breast cancer (44). This evidence concerns the gene BRCA1 and breast carcinoma.